Overview

Sitagliptin Added-on to Insulin Study (0431-051)

Status:
Completed

Trial end date:
2008-10-13

Target enrollment:

Participant gender:

Summary

A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on insulin or insulin/metformin combination therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Sitagliptin Phosphate